Canada markets closed

ICL Group Ltd (ICL)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
4.6300+0.0700 (+1.54%)
At close: 04:00PM EDT
4.5800 -0.05 (-1.08%)
After hours: 04:05PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close4.5600
Open4.5900
Bid4.5800 x 1100
Ask4.8700 x 1400
Day's Range4.5750 - 4.6600
52 Week Range4.3000 - 6.7300
Volume500,345
Avg. Volume784,033
Market Cap6.051B
Beta (5Y Monthly)0.59
PE Ratio (TTM)9.26
EPS (TTM)0.5000
Earnings DateN/A
Forward Dividend & Yield0.19 (4.19%)
Ex-Dividend DateMar 14, 2024
1y Target Est5.30
  • Business Wire

    ICL Announces First Quarter 2024 Earnings Call

    TEL AVIV, Israel, April 15, 2024--ICL (NYSE: ICL) (TASE: ICL), a leading global specialty minerals company, today announced it plans to release first quarter 2024 results prior to the opening of the TASE market on Thursday, May 9, 2024.

  • Business Wire

    ICL Files 2023 Annual Report on Form 20-F

    TEL AVIV, Israel, March 14, 2024--ICL (NYSE: ICL) (TASE: ICL), a leading global specialty minerals company, today announced the filing of its annual report on Form 20-F for the fiscal year ended December 31, 2023, with the U.S. Securities and Exchange Commission (SEC). Included, for the third year in a row, are Task Force on Climate-related Financial Disclosures (TCFD), which provide information on what ICL is doing to mitigate the risks of climate change and reduce its carbon footprint.

  • Business Wire

    ICL Accelerating Biologicals Portfolio Growth in Brazil with Strategic Acquisition

    TEL AVIV, Israel, February 28, 2024--ICL (NYSE: ICL) (TASE: ICL), a leading global specialty minerals company, today announced it has acquired Nitro 1000, a manufacturer, developer and provider of biologicals in Brazil for approximately $30 million. This acquisition marks another meaningful step into the biologicals market, while expanding ICL’s product offerings and positioning the company for further expansions into new and adjacent end-markets.